Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab Combined With Chemotherapy as Neoadjuvant Therapy in Locally Advanced Hypopharyngeal Carcinoma
NCT07752394Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2031
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab in hypopharyngeal carcinoma (HPC), sponsored by Tangdu Hospital. Primary endpoint: Major pathological response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
penpulimab
03
Conditions
hypopharyngeal carcinoma (HPC)
Beyond the preview
Go deeper on NCT07752394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07752394.